Drake & Associates’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.54M Buy
1,334
+121
+10% +$143K 0.24% 32
2026
Q2
$1.45M Buy
1,213
+546
+82% +$558K 0.25% 30
2026
Q1
$614K Sell
667
-129
-16% -$131K 0.12% 64
2025
Q4
$856K Sell
796
-77
-9% -$73.6K 0.17% 63
2025
Q3
$809K Sell
873
-27
-3% -$20.1K 0.17% 67
2025
Q2
$702K Buy
900
+54
+6% +$42K 0.17% 59
2025
Q1
$699K Buy
846
+113
+15% +$94K 0.2% 49
2024
Q4
$644K Sell
733
-646
-47% -$535K 0.18% 51
2024
Q3
$1.22M Buy
1,379
+133
+11% +$120K 0.39% 23
2024
Q2
$1.13M Sell
1,246
-113
-8% -$90.4K 0.4% 22
2024
Q1
$1.06M Buy
1,359
+15
+1% +$10.7K 0.39% 24
2023
Q4
$784K Sell
1,344
-436
-24% -$254K 0.32% 25
2023
Q3
$956K Buy
1,780
+24
+1% +$12.4K 0.43% 23
2023
Q2
$824K Sell
1,756
-24
-1% -$10.1K 0.37% 23
2023
Q1
$611K Buy
1,780
+47
+3% +$15.9K 0.3% 28
2022
Q4
$634K Buy
1,733
+83
+5% +$29.4K 0.34% 24
2022
Q3
$534K Buy
1,650
+661
+67% +$209K 0.3% 21
2022
Q2
$321K Buy
+989
New +$297K 0.18% 32

Other funds holding LLY

Drake & Associates's LLY Position: Q3 2026 in Review

Drake & Associates increased its Eli Lilly (LLY) stake by 10% in Q3 2026, buying an estimated $143K and bringing the position to 1,334 shares worth $1.54M. The position accounts for 0.24% of the portfolio, ranked #32.

Drake & Associates first reported a position in LLY in Q2 2022 and has held it in 18 quarters since. 4,625 funds tracked by Wall St. Rank hold LLY as of Q3 2026.

  • Drake & Associates held 1,334 shares of Eli Lilly worth $1.54M as of Q3 2026.
  • Drake & Associates bought 121 Eli Lilly shares in Q3 2026, an estimated $143K.
  • Eli Lilly made up 0.24% of Drake & Associates's portfolio in Q3 2026, its #32 holding.
  • Drake & Associates first reported a position in Eli Lilly in Q2 2022 and has held it in 18 quarters since.
  • 4,625 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.

Based on Drake & Associates's 13F filing for Q3 2026, filed 18 Nov 2026.